the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Dec 21, 2023 → Dec 31, 2025
NCT ID
NCT06206135About the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) is a pre-clinical stage product being developed by Kyowa Kirin for Hyperphosphatemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06206135. Target conditions include Hyperphosphatemia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06206135 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Hyperphosphatemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EOS789 + Placebo + Renvela | Chugai Pharmaceutical | Phase 1 | 33 |
| DS-2330b PIB + Placebo + Sevelamer + DS-2330b Tablet | Daiichi Sankyo | Phase 1 | 33 |
| ASP1585 + Placebo + Sevelamer hydrochloride | Astellas Pharma | Phase 2 | 52 |
| ASP1585 | Astellas Pharma | Phase 2 | 52 |
| the standard-dose group (4 g/day) | Kyowa Kirin | Pre-clinical | 23 |
| KHK7791 + Placebp | Kyowa Kirin | Phase 2 | 52 |
| KHK7791 | Kyowa Kirin | Phase 2 | 52 |
| KHK7791 + Placebo | Kyowa Kirin | Phase 3 | 77 |
| KHK7791 + Placebo | Kyowa Kirin | Phase 3 | 77 |
| KHK7791 | Kyowa Kirin | Phase 3 | 77 |
| KHK7791 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| KHK7791 | Kyowa Kirin | Phase 3 | 77 |
| SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl | Novartis | Phase 2 | 52 |
| SBR759A + SBR759A + SBR759A + SBR759A + SBR759A | Novartis | Phase 3 | 77 |
| PA21 | Kissei Pharmaceutical | Phase 3 | 76 |
| Placebo + Sevelamer Carbonate (GZ419831) | Sanofi | Phase 3 | 76 |
| Placebo + Sevelamer carbonate | Sanofi | Phase 2 | 51 |
| Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet | Bayer | Pre-clinical | 20 |
| Lanthanum Carbonate (Fosrenol, BAY77-1931) | Bayer | Pre-clinical | 20 |
| Lanthanum Carbonate (BAY77-1931) | Bayer | Phase 2 | 49 |